This review focuses on the most widely used methods for measuring BCF within thecontext of insulin resistance and includes examples of their use in prediabetes and T2DM, with an emphasis on the mostrecent therapeutic options (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.